Related content

Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy

By Kono Toru   Hata Taishi   Morita Satoshi   Munemoto Yoshinori   Matsui Takanori   Kojima Hiroshi   Takemoto Hiroyoshi   Fukunaga Mutsumi   Nagata Naoki   Shimada Mitsuo   Sakamoto Junichi   Mishima Hideyuki  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 6, 2013-12 ,pp. : 1283-1290

Springer Publishing Company

Access to resources Recommend Favorite

Oxaliplatin-induced immune mediated thrombocytopenia

By Beg Muhammad  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 5, 2008-10 ,pp. : 925-927

Springer Publishing Company

Access to resources Recommend Favorite

Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective

By Cortinovis D.   Alberti P.   Frigeni B.   Bidoli P.   Cavaletti G.  

Annals of Oncology, Vol. 24, Iss. 5, 2013-05 ,pp. : 1418-1419

Oxford University Press

Access to resources Recommend Favorite

Acute renal failure related to oxaliplatin-induced intravascular hemolysis

By Ulusakarya Ayhan  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1425-1426

Humana Press, Inc

Access to resources Recommend Favorite

Oxaliplatin-induced Haematological Emergency with an Immediate Severe Thrombocytopenia and Haemolysis

By Sørbye Halfdan   Bruserud Øystein   Dahl Olav  

Acta Oncologica, Vol. 40, Iss. 7, 2001-11 ,pp. : 882-883

Informa Healthcare

Access to resources Recommend Favorite